Sugi Predict

Sugi Predict / Compounds / SCHEMBL258829

SCHEMBL258829

SCHEMBL258829

Nc1nc2c(C3OC(CO)C(O)C3O)coc2c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 5/20 0.53
▸ CYP3A4 P08684 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ EIF4E P06730 2/20 0.38
▸ TLR7 Q9NYK1 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ GMNN O75496 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ STAT6 P42226 1/20 0.37
▸ HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308717 1.00 PNP (0.53) PNPCYP3A4MAPTMEN1KMT2A
SCHEMBL260736 1.00 PNP (0.53) PNPCYP3A4MAPTMEN1KMT2A
SCHEMBL260738 1.00 PNP (0.53) PNPCYP3A4MAPTMEN1KMT2A
SCHEMBL3302990 0.79 PNP (0.81) PNP
SCHEMBL3309836 0.79 PNP (0.53) PNPCYP3A4MAPTMEN1KMT2A
SCHEMBL3309845 0.79 PNP (0.53) PNPCYP3A4MAPTMEN1KMT2A
SCHEMBL3302997 0.79 PNP (0.81) PNP
SCHEMBL3300632 0.79 PNP (0.52) PNPMEN1KMT2AKDM4E
SCHEMBL3300636 0.79 PNP (0.52) PNPMEN1KMT2AKDM4E
SCHEMBL2104845 0.79 PNP (0.52) PNPMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 — — US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 — — US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 — — US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 — — US disclosed
US-20060165655-A1 Therapeutic furopyrimidines and thienopyrimidines WILMINGTON TRUST, NATIONAL ASSOCIATION 2006-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS PNP 23/4885CYP3A4 897/4885MAPT 3672/4885
US-20060165655-A1 Therapeutic furopyrimidines and thienopyrimidines DPYD, TYMP, TYMS PNP 23/4885CYP3A4 897/4885MAPT 3672/4885
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES DPYD, TYMP, TYMS PNP 23/4885CYP3A4 897/4885MAPT 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.